Thermo Fisher adds Affinity to protein research offering
This article was originally published in Clinica
Executive Summary
Laboratory equipment manufacturer Thermo Fisher Scientific has purchased antibody provider Affinity BioReagents in a move that increases its antibody offering and complements its protein research capabilities. Waltham, Massachusetts-based Thermo Fisher paid an undisclosed amount to secure Affinity, which will be integrated into the firm’s analytical technologies business. According to Thermo Fisher CEO Marijn Dekkers, this acquisition will allow the company to create end-to-end solutions for protein research applications such as Western blotting, ELISA, immunohistochemistry, flow cytometry and mass spectroscopy. Affinity (Golden, Colorado) recorded revenues of $6m for fiscal 2007 and claims to own more than 35,000 reagents.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals